Charles Schwab Investment Management Inc Summit Therapeutics Inc. Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,016,545 shares of SMMT stock, worth $7.66 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,016,545
Previous 953,846
6.57%
Holding current value
$7.66 Million
Previous $2.49 Million
69.06%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding SMMT
# of Institutions
107Shares Held
41.3MCall Options Held
103KPut Options Held
29.9K-
Black Rock Inc. New York, NY9.82MShares$74.1 Million0.0% of portfolio
-
State Street Corp Boston, MA8.11MShares$61.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.27MShares$54.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.15MShares$23.8 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL1.07MShares$8.09 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $1.52B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...